Table 3 Effects of modulation of dCK and hENT on gemcitabine (dFdC, 1 h) and gemcitabine-pemetrexed (MTA) combinations IC50s (nM) in T24 and J82 cells. Values are means±s.d. of at least three separate experiments

From: In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients

Cell lines

Treatments

IC 50

+Deoxycytidine

+Dipyridamole

+NBMPR

 

dFdC

91.7±5.1

157.7±23.7

4513.4±909.5

7475.3±1337.3

T24

dFdC-MTA

47.3±5.0

72.3±13.7

78.0±87.3

67.7±9.7

 

MTA-dFdC

10.3±2.0

12.6±8.7

49.1±6.2

48.7±6.5

 

dFdC

4366.7±833.3

5863.0±234.5

4959.7±109.1

4476.5±801.3

J82

dFdC-MTA

83.3±12.0

108.1±7.7

86.7±11.8

85.7±4.3

 

MTA-dFdC

100.0±9.7

111.1±12.3

101.3±2.7

99.7±5.2

Back to article page